Nautilus Biotechnology

About:

Nautilus Biotechnology offers a high-throughput, low-cost platform for analyzing and quantifying the human proteome.

Website: https://www.nautilus.bio

Top Investors: Andreessen Horowitz, RA Capital Management, Franklin Templeton, OrbiMed, Bezos Expeditions

Description:

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

Total Funding Amount:

$303M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

San Carlos, California, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)nautilus.bio

Founders:

Parag Mallick, Sujal Patel

Number of Employees:

101-250

Last Funding Date:

2021-06-10

IPO Status:

Public

© 2025 bioDAO.ai